Philipp Haber

Dr. Philipp Haber


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FKFelix Krenzien
Felix Krenzien
NNNora Nevermann
Nora Nevermann
AKAlina Krombholz
Alina Krombholz
CBChristian Benzing
Christian Benzing
PHPhilipp Haber
Philipp Haber
WSWenzel Schöning
Wenzel Schöning
Intrahepatic cholangiocarcinoma (iCC) is distinguished as an entity from perihilar and distal cholangiocarcinoma and gallbladder carcinoma. Recently, molecular profiling and histopathological features have allowed further classification. Due to the frequent delay in diagnosis, the prognosis for iCC remains poor despite major technical advances and multimodal therapeutic approaches. Liver resection represents the therapeutic backbone and only curative treatment option, with the functional residual capacity of the liver and oncologic radicality being deciding factors for postoperative and long-term oncological outcome. Furthermore, in selected cases and depending on national guidelines, liver transplantation may be a therapeutic option. Given the often advanced tumor stage at diagnosis or the potential for postoperative recurrence, locoregional therapies have become increasingly important. These strategies range from radiofrequency ablation to transarterial chemoembolization to selective internal radiation therapy and can be used in combination with liver resection. In addition, adjuvant and neoadjuvant chemotherapies as well as targeted therapies and immunotherapies based on molecular profiles can be applied. This review discusses multimodal treatment strategies for iCC and their differential use.

10 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PHPhilipp Haber
Philipp Haber
CMChristoph Maier
Christoph Maier
AKAnika Kästner
Anika Kästner
LFLinda Feldbrügge
Linda Feldbrügge
SGSantiago Ortiz Galindo
Santiago Ortiz Galindo
MSMoritz Schmelzle
Moritz Schmelzle
Minimal-invasive techniques are increasingly applied in clinical practice and have contributed towards improving postoperative outcomes. While comparing favorably with open surgery in terms of safety, the occurrence of severe complications remains a grave concern. To date, no objective predictive system has been established to guide clinicians in estimating complication risks as the relative contribution of general patient health, liver function and surgical parameters remain unclear. Here, we perform a single-center analysis of all consecutive patients undergoing laparoscopic liver resection for primary hepatic malignancies since 2010. Among the 210 patients identified, 32 developed major complications. Several independent predictors were identified through a multivariate analysis, defining a preoperative model: diabetes, history of previous hepatectomy, surgical approach, alanine aminotransferase levels and lesion entity. The addition of operative time and whether conversion was required significantly improved predictions and were thus incorporated into the postoperative model. Both models were able to identify patients with major complications with acceptable performance (area under the receiver-operating characteristic curve (AUC) for a preoperative model = 0.77 vs. postoperative model = 0.80). Internal validation was performed and confirmed the discriminatory ability of the models. An easily accessible online tool was deployed in order to estimate probabilities of severe complication without the need for manual calculation.

20 January 2025 in The Lancet Oncology
Verified
Journal Article
Closed access
LSLaura Stöffler
Laura Stöffler
DMDominik Paul Modest
Dominik Paul Modest
JPJohann Pratschke
Johann Pratschke
PHPhilipp Haber
Philipp Haber